X @Wendy O

Company Strategy - MEI Pharma purchased $100 million in Litecoin (LTC) as a treasury asset [1][2] - MEI Pharma is the first U_S_-listed company to adopt Litecoin as a primary treasury asset [2] - MEI Pharma funded the purchase via a $100 million private placement led by Charlie Lee [2] - MEI Pharma may expand into LTC mining [2] - MEI Pharma continues drug development while pioneering a crypto treasury strategy [2] Litecoin Adoption - MEI Pharma cites LTC's 13-year uptime, low fees, fast settlement, and mainstream integrations as reasons for adoption [2] Investment - Charlie Lee and GSR are lead investors in the private placement [1]